Literature DB >> 15275738

X-irradiation to human malignant glioma cells enhances the cytotoxicity of autologous killer lymphocytes under specific conditions.

Eiichi Ishikawa1, Koji Tsuboi, Kaoru Saijo, Shingo Takano, Tadao Ohno.   

Abstract

PURPOSE: To clarify the effect of combining x-irradiation and human killer lymphocytes against autologous malignant glioma cells, we analyzed not only the alteration of surface antigen expression in irradiated tumor cells, but also the cytotoxic effects of human killer lymphocytes on the autologous tumor cells with and without x-irradiation. METHODS AND MATERIALS: Six malignant glioma cell-lines (MG 1-6) established from each patient with a malignant glioma in our institute, and U87MG, were used as materials. They were irradiated by 0-50 Gy of X-rays, and the alternations of their human histocompatability leukocyte antigen (HLA), HLA-ABC, HLA-DR, -DP, -DQ, and FAS expressions were examined. Then, three sets of autologous natural killer (NK) cells, and autologous tumor-specific T lymphocytes (ATTL) were induced from the peripheral blood mononuclear cells (PBMCs) of three patients, and in vitro cytotoxic effects of these killer cells on the irradiated autologous tumor cells were analyzed.
RESULTS: Irradiation-enhanced HLA-DR, -DP, -DQ, and FAS expression in glioma cell lines with low p53 expression. However, there was no correlation between HLA-ABC expression and X-ray dose. After irradiation of the tumor cells, cytotoxicity was enhanced in four of six effectors; in particular, it was significantly elevated in two killer lymphocytes. It was speculated that the enhancing effect was influenced not only by the p53 status of the tumor, but also by the types of killer lymphocytes; the alteration of cytotoxicity in NK cells on irradiated tumor cells may be compensatory for alteration in ATTLs.
CONCLUSION: It was indicated that irradiation of malignant tumor cells enhanced killer cell-mediated cytotoxicity in autologous models under specific conditions. These basic data should contribute to clinical trials using local radiotherapy and systemic adoptive immunotherapy with killer lymphocytes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15275738     DOI: 10.1016/j.ijrobp.2004.04.046

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  9 in total

1.  Vaccines as monotherapy and in combination therapy for prostate cancer.

Authors:  Julia Rotow; Sofia R Gameiro; Ravi A Madan; James L Gulley; Jeffrey Schlom; James W Hodge
Journal:  Clin Transl Sci       Date:  2010-06       Impact factor: 4.689

2.  Radiation-induced tumor neoantigens: imaging and therapeutic implications.

Authors:  Christopher D Corso; Arif N Ali; Roberto Diaz
Journal:  Am J Cancer Res       Date:  2011-01-25       Impact factor: 6.166

Review 3.  Combination regimens of radiation therapy and therapeutic cancer vaccines: mechanisms and opportunities.

Authors:  Charlie Garnett-Benson; James W Hodge; Sofia R Gameiro
Journal:  Semin Radiat Oncol       Date:  2015-01       Impact factor: 5.934

4.  Enhancing cytokine-induced killer cell therapy of multiple myeloma.

Authors:  Chunsheng Liu; Lukkana Suksanpaisan; Yun-Wen Chen; Stephen J Russell; Kah-Whye Peng
Journal:  Exp Hematol       Date:  2013-02-08       Impact factor: 3.084

5.  Eradication of breast cancer with bone metastasis by autologous formalin-fixed tumor vaccine (AFTV) combined with palliative radiation therapy and adjuvant chemotherapy: a case report.

Authors:  Fumito Kuranishi; Tadao Ohno
Journal:  World J Surg Oncol       Date:  2013-06-04       Impact factor: 2.754

6.  Enhancement of natural killer cell cytotoxicity by sodium/iodide symporter gene-mediated radioiodine pretreatment in breast cancer cells.

Authors:  Hae Won Kim; Jung Eun Kim; Mi-Hye Hwang; Yong Hyun Jeon; Sang-Woo Lee; Jaetae Lee; Seok Kil Zeon; Byeong-Cheol Ahn
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

7.  A phase I study on combined therapy with proton-beam radiotherapy and in situ tumor vaccination for locally advanced recurrent hepatocellular carcinoma.

Authors:  Masato Abei; Toshiyuki Okumura; Kuniaki Fukuda; Takayuki Hashimoto; Masahiro Araki; Kazunori Ishige; Ichinosuke Hyodo; Ayae Kanemoto; Haruko Numajiri; Masashi Mizumoto; Takeji Sakae; Hideyuki Sakurai; Junko Zenkoh; Gerelchuluun Ariungerel; Yu Sogo; Atsuo Ito; Tadao Ohno; Koji Tsuboi
Journal:  Radiat Oncol       Date:  2013-10-16       Impact factor: 3.481

8.  Long-lasting complete response status of advanced stage IV gall bladder cancer and colon cancer after combined treatment including autologous formalin-fixed tumor vaccine: two case reports.

Authors:  Yuki Imaoka; Fumito Kuranishi; Tsubasa Miyazaki; Hiroko Yasuda; Tadao Ohno
Journal:  World J Surg Oncol       Date:  2017-09-11       Impact factor: 2.754

Review 9.  Narrative review of immunotherapy and radiation therapy in elderly patients.

Authors:  Brittney Chau; Jonnby LaGuardia; Caressa Hui; Linda Ye; Yan Xing; Erminia Massarelli; Arya Amini
Journal:  Transl Cancer Res       Date:  2021-05       Impact factor: 1.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.